Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

The role of human papillomavirus testing in the management of women with low-grade abnormalities: multicentre randomised controlled trial.

Cotton S, Sharp L, Little J, Cruickshank M, Seth R, Smart L, Duncan I, Harrild K, Neal K, Waugh N; Trial Of Management of Borderline and Other Low-grade Abnormal Smears Group.

BJOG. 2010 May;117(6):645-59. doi: 10.1111/j.1471-0528.2010.02519.x.

2.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

4.

Management of women with low grade cytology: how reassuring is a normal colposcopy examination?

Cruickshank ME, Cotton SC, Sharp L, Smart L, Walker LG, Little J; TOMBOLA Group.

BJOG. 2015 Feb;122(3):380-6. doi: 10.1111/1471-0528.12932. Epub 2014 Jun 20.

6.

Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test.

Kyrgiou M, Kalliala IE, Mitra A, Fotopoulou C, Ghaem-Maghami S, Martin-Hirsch PP, Cruickshank M, Arbyn M, Paraskevaidis E.

Cochrane Database Syst Rev. 2017 Jan 26;1:CD009836. doi: 10.1002/14651858.CD009836.pub2. Review.

PMID:
28125861
7.

Human papillomavirus type 16 and 18 detection in the management of mild dyskaryosis.

Cruickshank ME, Buchan S, Melvin WT, Kitchener HC.

Br J Obstet Gynaecol. 1999 Sep;106(9):969-76.

PMID:
10492111
8.

HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study.

Kelly RS, Patnick J, Kitchener HC, Moss SM; NHSCSP HPV Special Interest Group.

Br J Cancer. 2011 Sep 27;105(7):983-8. doi: 10.1038/bjc.2011.326. Epub 2011 Sep 6.

9.

Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.

Carozzi F, Gillio-Tos A, Confortini M, Del Mistro A, Sani C, De Marco L, Girlando S, Rosso S, Naldoni C, Dalla Palma P, Zorzi M, Giorgi-Rossi P, Segnan N, Cuzick J, Ronco G; NTCC working group.

Lancet Oncol. 2013 Feb;14(2):168-76. doi: 10.1016/S1470-2045(12)70529-6. Epub 2012 Dec 21.

PMID:
23261355
10.

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM.

Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7. Epub 2011 Aug 22.

PMID:
21865084
11.

Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months.

Bulk S, Bulkmans NW, Berkhof J, Rozendaal L, Boeke AJ, Verheijen RH, Snijders PJ, Meijer CJ.

Int J Cancer. 2007 Jul 15;121(2):361-7. Erratum in: Int J Cancer. 2007 Oct 15;121(8):1873.

12.

Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.

Canfell K, Caruana M, Gebski V, Darlington-Brown J, Heley S, Brotherton J, Gertig D, Jennett CJ, Farnsworth A, Tan J, Wrede CD, Castle PE, Saville M.

PLoS Med. 2017 Sep 19;14(9):e1002388. doi: 10.1371/journal.pmed.1002388. eCollection 2017 Sep.

13.

Human papillomavirus test with cytology triage in organized screening for cervical cancer.

Veijalainen O, Kares S, Kujala P, Tirkkonen M, Vuento R, Kholová I, Luukkaala T, Osuala V, Mäenpää J.

Acta Obstet Gynecol Scand. 2016 Nov;95(11):1220-1227. doi: 10.1111/aogs.13013.

PMID:
27591407
14.

High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance.

Denise Zielinski G, Snijders PJ, Rozendaal L, Voorhorst FJ, Runsink AP, de Schipper FA, Meijer CJ.

J Pathol. 2001 Oct;195(3):300-6.

PMID:
11673826
15.

High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.

Rijkaart DC, Heideman DA, Coupe VM, Brink AA, Verheijen RH, Skomedal H, Karlsen F, Morland E, Snijders PJ, Meijer CJ.

J Clin Microbiol. 2012 Jul;50(7):2390-6. doi: 10.1128/JCM.06587-11. Epub 2012 May 2.

16.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

PMID:
19903804
17.

Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.

Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N; New Technologies for Cervical Cancer Screening Working Group.

J Natl Cancer Inst. 2008 Apr 2;100(7):492-501. doi: 10.1093/jnci/djn065. Epub 2008 Mar 25.

PMID:
18364502
18.

Management of women who test positive for high-risk types of human papillomavirus: the HART study.

Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P.

Lancet. 2003 Dec 6;362(9399):1871-6.

PMID:
14667741
19.

Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.

Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA.

JAMA. 2002 Oct 9;288(14):1749-57.

PMID:
12365959
20.

Incidence of cervical intraepithelial neoplasia grade 2 or worse in colposcopy-negative/human papillomavirus-positive women with low-grade cytological abnormalities.

Kelly RS, Walker P, Kitchener H, Moss SM.

BJOG. 2012 Jan;119(1):20-5. doi: 10.1111/j.1471-0528.2011.02970.x. Epub 2011 May 31.

Supplemental Content

Support Center